{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:46:54Z","timestamp":1761490014472},"reference-count":12,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Clinica Belgica"],"published-print":{"date-parts":[[1989,1]]},"DOI":"10.1080\/17843286.1989.11717996","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T16:21:14Z","timestamp":1464020474000},"page":"99-109","source":"Crossref","is-referenced-by-count":5,"title":["Imipenem\/Cilastatin Versus Imperacillin Plus Amikacin as Empiric Therapy in the Treatment of Febrile Episodes in Neutropenic Patients With Haematologic Malignancies"],"prefix":"10.1080","volume":"44","author":[{"given":"B.","family":"Vandercam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ezzeddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Agaliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Gala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Michaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,5,21]]},"reference":[{"key":"CIT0003","doi-asserted-by":"crossref","unstructured":"Pizzo PA, Thaler M, Hathorn J et al. New be-ta-lactam antibiotics in granulocytopenic patients: new options and new questions.Am J Med.1985; 79 suppl 2A: 75\u201382.","DOI":"10.1016\/0002-9343(85)90265-7"},{"key":"CIT0004","doi-asserted-by":"crossref","unstructured":"Wade JC, Standiford HC, Drusano GL et al. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.Am J Med.1985; 78 suppl 6A: 62\u201372.","DOI":"10.1016\/0002-9343(85)90103-2"},{"key":"CIT0009","unstructured":"Labia R. The beta-lactamase stability of imipenem. Imipenem Congress: a unique and significant advance in antibiotic therapy, 1986 April 25\u201326, Rome, Italy."},{"key":"CIT0012","doi-asserted-by":"crossref","unstructured":"Salata RA, Gebhart RL, Palmer DL ct al. Pneumonia treated with imipenem\/cilastatin.Am J Med.1985; 78 suppl 6A: 104\u20139.","DOI":"10.1016\/0002-9343(85)90110-X"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Baquero F, Culebras E, Patron C, Perez-Dias JC, Medrano JC, Vicente MF. Postantibiotic effect of imipenem on gram-positive and gram-negative bacteria.J Antimicrob Chemother.1986; 18 suppl E ; 47\u201359.","DOI":"10.1093\/jac\/18.Supplement_E.47"},{"key":"CIT0025","doi-asserted-by":"crossref","unstructured":"Johnson DE, Calia FM, Snyder MJ, Warren JW, Schimpff SC. Imipenem therapy of Pseudomonas aeruginosa bacteraemia in neutropenic rats. JAntimicrob Chemother.1983; 12 suppl D: 89\u201396.","DOI":"10.1093\/jac\/12.suppl_D.89"},{"key":"CIT0026","doi-asserted-by":"crossref","unstructured":"Bodey C.P, Rolston K, Jones P, Alvarez ME, Fainstein V, Steelhammer L. Imipenem\/cilastatin as secondary therapy for infections in cancer patients. JAntimicrob Chemother.1986; 18 suppl E: 161\u20136.","DOI":"10.1093\/jac\/18.Supplement_E.161"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"Bodey GP, Alvarez ME, Jones PG, Rolston KV, Steelhammer L, Fainstein V. Imipenem-\/cilastatin as initial therapy for febrile cancer patients.Antimicrob Agents Chemother.1986; 30; 211\u201314.","DOI":"10.1128\/AAC.30.2.211"},{"key":"CIT0028","unstructured":"Dc Jongh CA, Joshi JH, Thompson BW et al. A double beta-lactam combination versus an aminoglyucoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.Am J Med.1986; 80 suppl 5C:101\u201311."},{"key":"CIT0030","doi-asserted-by":"crossref","unstructured":"Fainstein V, Bodey GP, Elting L et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients.J Antimicrob Chemother.1983; 12 suppl A: 101\u201310.","DOI":"10.1093\/jac\/12.suppl_A.101"},{"key":"CIT0035","doi-asserted-by":"crossref","unstructured":"Scully BE, Parry MF, Ncu HC, Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.Lancet.1986; i: 19\u201322.","DOI":"10.1016\/S0140-6736(86)90937-2"},{"key":"CIT0036","doi-asserted-by":"crossref","unstructured":"Trendholme GM, Pottage JC, Karakusis PII. Use of ceftazidime in the treatment of nosocomial lower respiratory infections.Am J Med.1985; 79 suppl 2A: 32\u20136.","DOI":"10.1016\/0002-9343(85)90258-X"}],"container-title":["Acta Clinica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17843286.1989.11717996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T13:21:26Z","timestamp":1567948886000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17843286.1989.11717996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,1]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,5,21]]},"published-print":{"date-parts":[[1989,1]]}},"alternative-id":["10.1080\/17843286.1989.11717996"],"URL":"https:\/\/doi.org\/10.1080\/17843286.1989.11717996","relation":{},"ISSN":["1784-3286","2295-3337"],"issn-type":[{"value":"1784-3286","type":"print"},{"value":"2295-3337","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,1]]}}}